Proteins > Proto-oncogene tyrosine-protein kinase Src
Page last updated: 2024-08-07 12:49:04
Proto-oncogene tyrosine-protein kinase Src
A proto-oncogene tyrosine-protein kinase Src that is encoded in the genome of chicken. [OMA:P00523, PRO:DNx]
Synonyms
EC 2.7.10.2;
Proto-oncogene c-Src;
pp60c-src;
p60-Src
Research
Bioassay Publications (14)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
Compounds (24)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| ag 1879 | Gallus gallus (chicken) | Kd | 0.2960 | 1 | 1 |
| imatinib | Gallus gallus (chicken) | Kd | 0.0128 | 2 | 2 |
| s 1033 | Gallus gallus (chicken) | Kd | 0.0130 | 2 | 2 |
| dasatinib | Gallus gallus (chicken) | Kd | 0.0037 | 2 | 3 |
| ponatinib | Gallus gallus (chicken) | Kd | 0.0007 | 2 | 2 |
| dcc-2036 | Gallus gallus (chicken) | Kd | 0.0091 | 2 | 2 |
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.Journal of medicinal chemistry, , 02-09, Volume: 60, Issue:3, 2017
Irreversible protein kinase inhibitors: balancing the benefits and risks.Journal of medicinal chemistry, , Jul-26, Volume: 55, Issue:14, 2012
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.Bioorganic & medicinal chemistry, , Apr-01, Volume: 16, Issue:7, 2008
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.ACS chemical biology, , 05-20, Volume: 11, Issue:5, 2016
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Journal of medicinal chemistry, , Jul-25, Volume: 56, Issue:14, 2013
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.ACS chemical biology, , 05-20, Volume: 11, Issue:5, 2016
A new screening assay for allosteric inhibitors of cSrc.Nature chemical biology, , Volume: 5, Issue:6, 2009
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.Journal of medicinal chemistry, , Jul-09, Volume: 52, Issue:13, 2009
2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.Journal of medicinal chemistry, , May-21, Volume: 41, Issue:11, 1998
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.Journal of medicinal chemistry, , May-21, Volume: 41, Issue:11, 1998
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.Journal of medicinal chemistry, , May-21, Volume: 41, Issue:11, 1998
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.ACS chemical biology, , 05-20, Volume: 11, Issue:5, 2016
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Journal of medicinal chemistry, , Jul-25, Volume: 56, Issue:14, 2013